Sign In
Buy DFFN
$5.87
+0 (+0%)
At Close: Nov 28, 2023
Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June
01:20pm, Wednesday, 09'th Jun 2021
Hot Penny Stocks Under $1 To Watch This Month The post Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
07:05am, Monday, 10'th May 2021
CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel t
Top Biotech Penny Stocks on Reddit? Check These 3 Out
02:45pm, Friday, 30'th Apr 2021
Biotech penny stocks are back in focus; should these 3 be on your watchlist? The post Top Biotech Penny Stocks on Reddit?
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
09:01am, Thursday, 25'th Mar 2021
CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel
Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update
07:05am, Wednesday, 17'th Mar 2021
CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock
04:13pm, Wednesday, 17'th Feb 2021
CHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel
DFFN Stock Price Increases Over 20% Pre-Market: Why It Happened
09:02am, Tuesday, 16'th Feb 2021
The stock price of Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) is trading at over 20% pre-market. This is why it happened.
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
07:35am, Tuesday, 16'th Feb 2021
No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million
10:02pm, Thursday, 11'th Feb 2021
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company de
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
05:54pm, Thursday, 11'th Feb 2021
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company de
Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference
07:30am, Monday, 11'th Jan 2021
CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
04:02pm, Thursday, 12'th Nov 2020
Initiated and Advanced C linical Trial Evaluating Lead Product Candidate in COVID-19 Patients
Акции «Яндекса» на рекордном уровне: аналитики одобряют сделку с «Тинькофф Банк»
10:55am, Thursday, 24'th Sep 2020
Инвесторы вкладываются в акции «Яндекса» после сделки, которая сделает технологический гигант ведущей росс�
Ligand Acquisitions, And Other News: The Good, Bad And Ugly Of Biopharma
02:16pm, Monday, 14'th Sep 2020
Ligand inks deal to acquire Taurus and xCella Biosciences. Zogenix reports positive data from pivotal Phase 3 clinical trial.
Insider Buys TriState Capital's Shares
12:00am, Wednesday, 19'th Aug 2020
TriState Capital Holdings Inc (NASDAQ:TSC) was trading 1.3% higher from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, August 19 showed that CEO TSC...
